Veterans Affairs (VA) Signs Agreement with Theranica to Make Nerivio® Acute Migraine Therapeutic Device Available to Veterans
Drug-Free Smartphone-Controlled Wearable Device Will Address Veteran Community, which has Higher Prevalence Migraine Compared to the General Population
16 Feb, 2021, 08:00 ET
MONTCLAIR, N.J., Feb. 16, 2021 /PRNewswire/ -- Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced it has signed a Federal Supply Schedule (FSS) agreement with the United States Department of Veterans Affairs (VA), that will enable Veterans access to Nerivio®, a wearable for acute treatment of migraine.
"Nerivio has shown clinical efficacy for episodic and chronic migraine, both in clinical trials and real-world evidence analyses," said Jason Sico, MD, Associate Professor of Neurology and Internal Medicine in Yale School of Medicine. "Providing headache care to both Veterans and non-Veterans, it has been my experience that Veterans tend to live with migraine and related headache disorders at higher rates than the general population. Making available effective treatments is extremely important. Drug free options like Nerivio resonate with the values and preferences of many Veterans."
A number of studies have outlined the prevalence of migraine amongst Veterans. 36% of Veterans who completed a 12-month deployment to Iraq exhibit symptoms of migraine - 3 times higher than the general population. Over nine million Veterans are enrolled in the VA health care system.
"As a US Navy veteran, I feel gratified to be able to provide Veterans who suffer from migraine access to Nerivio", said Scott Szymanski, President Theranica US. "Veterans are one of the most at-risk populations for migraine and other headache disorders. We are committed to have Nerivio improve the quality of life of Veterans receiving medical care within the VA system, as well as those that are making the transition back to civilian life."
"The VA is a role model for putting the well-being of its members at the highest priority," said Alon Ironi, CEO and Co-founder of Theranica. "We are also in the process of negotiating agreements with several commercial health insurance organizations. A significant amount of clinical data has solidified that Nerivio® provides an effective and safe non-pharmacological alternative for treating migraine both in adults and adolescents, while also allowing patients and physicians to track the disease and understand how to best manage it through the Nerivio mobile application."
Theranica's FDA-cleared prescribed therapeutic wearable Nerivio® is worn on the upper arm upon onset of a migraine attack, and utilizes technology called Remote Electrical Neuromodulation to activate the brain's native Conditioned Pain Modulation mechanism to treat pain and associated migraine symptoms. Nerivio was cited as one of TIME's best inventions of 2019.
(Views expressed by Dr. Sico are his own, and do not necessarily represent the Department of Veterans Affairs)
Theranica is a prescribed digital therapeutics company dedicated to creating effective, safe, affordable, low side-effect electroceuticals for idiopathic pain conditions. The company's award-winning flagship product, Nerivio®, is the first FDA-cleared smartphone-controlled prescription wearable device for acute migraine treatment of episodic or chronic migraine in people 12 years and older. Theranica is expanding its proprietary technology to offer additional solutions for other pain conditions. The Nerivio has received FDA authorization and the CE mark for use in acute treatment of migraine.
Learn more by visiting Nerivio's website and following us on LinkedIn, Twitter and Facebook.
Share this article